BENSALEM, Pa. / Apr 26, 2023 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) reported for the three months ended March 31, 2023 revenue of $417.2 million, GAAP net income of $12.7 million, or $0.17 per basic and diluted common share, and adjusted EBITDA of $27.5 million.
Q1 Results
Ted Wahl, Chief Executive Officer, stated, “We delivered strong operating results and service execution during the quarter, as our relentless focus on customer experience, systems adherence and regulatory compliance led to high quality and consistent outcomes for our client-partners. We successfully managed cost of services in line with our target of 86% and showed marked improvement in Q1 cash collections year over year in what has historically been our most challenging cash collections quarter. We also successfully exited the final tranche of facilities related to the 2022 contract modification initiative, providing a solid foundation for us to grow in the future.”
Mr. Wahl concluded, “Industry fundamentals continue to improve, and a stabilizing labor market and stronger reimbursement environment, especially at the state level, contributed to what has been a gradual occupancy recovery. Looking ahead, we are focused on executing on our strategic priorities to drive growth, and we remain confident in our ability to deliver long-term value to our shareholders.”
Conference Call and Upcoming Events
The Company will host a conference call on Wednesday, April 26, 2023, at 8:30 a.m. Eastern Time to discuss its results for the three months ended March 31, 2023. The call may be accessed via phone at 1 (888) 330-3451, Conference ID: 4431380. The call will be simultaneously webcast under the “Events & Presentations” section of the Investor Relations page on the Company’s website, www.hcsg.com. A replay of the webcast will also be available on the website for one year following the date of the earnings call.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This release and any schedules incorporated by reference into it may contain forward-looking statements within the meaning of federal securities laws, which are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions. Words such as “believes,” “anticipates,” “plans,” “expects,” “estimates,” “will,” “goal,” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Such forward-looking information is also subject to various risks and uncertainties. Such risks and uncertainties include, but are not limited to, risks arising from our providing services to the healthcare industry and primarily providers of long-term care; the impact of and future effects of the COVID-19 pandemic or other potential pandemics; having a significant portion of our consolidated revenues contributed by one customer during the three months ended March 31, 2023; credit and collection risks associated with the healthcare industry; the impact of bank failures; our claims experience related to workers’ compensation and general liability insurance (including any litigation claims, enforcement actions, regulatory actions and investigations arising from personal injury and loss of life related to COVID-19); the effects of changes in, or interpretations of laws and regulations governing the healthcare industry, our workforce and services provided, including state and local regulations pertaining to the taxability of our services and other labor-related matters such as minimum wage increases; the Company's expectations with respect to selling, general, and administrative expense; and the risk factors described in Part I of our Form 10-K for the fiscal year ended December 31, 2022 under “Government Regulation of Customers,” “Service Agreements and Collections,” and “Competition” and under Item 1A. “Risk Factors” in such Form 10-K.
These factors, in addition to delays in payments from customers and/or customers in bankruptcy, have resulted in, and could continue to result in, significant additional bad debts in the near future. Additionally, our operating results would be adversely affected by continued inflation particularly if increases in the costs of labor and labor-related costs, materials, supplies and equipment used in performing services (including the impact of potential tariffs and COVID-19) cannot be passed on to our customers.
In addition, we believe that to improve our financial performance we must continue to obtain service agreements with new customers, retain and provide new services to existing customers, achieve modest price increases on current service agreements with existing customers and/or maintain internal cost reduction strategies at our various operational levels. Furthermore, we believe that our ability to sustain the internal development of managerial personnel is an important factor impacting future operating results and the successful execution of our projected growth strategies. There can be no assurance that we will be successful in that regard.
USE OF NON-GAAP FINANCIAL INFORMATION
To supplement HCSG’s consolidated financial information, which are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), the Company believes that certain non-GAAP financial measures are useful in evaluating operating performance and comparing such performance to other companies.
The Company is presenting earnings before interest, taxes, depreciation and amortization ("EBITDA"), and excluding items impacting comparability ("Adjusted EBITDA"). We cannot provide a reconciliation of forward-looking EBITDA and Adjusted EBITDA margin measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. The presentation of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for financial statements prepared in accordance with GAAP.
HEALTHCARE SERVICES GROUP, INC. | |||||||
CONSOLIDATED STATEMENTS OF INCOME | |||||||
(Unaudited) | |||||||
(in thousands, except per share data) | |||||||
|
| For the Three Months Ended | |||||
|
| March 31, | |||||
|
| 2023 |
| 2022 |
| ||
Revenues |
| $ | 417,230 |
| $ | 426,811 |
|
Operating costs and expenses: |
|
|
|
| |||
Costs of services provided |
|
| 360,978 |
|
| 373,262 |
|
Selling, general and administrative |
|
| 40,047 |
|
| 35,736 |
|
Income from operations |
|
| 16,205 |
|
| 17,813 |
|
Other income (expense), net |
|
| 1,351 |
|
| (2,032 | ) |
Income before income taxes |
|
| 17,556 |
|
| 15,781 |
|
|
|
|
|
| |||
Income tax provision |
|
| 4,872 |
|
| 4,452 |
|
Net income |
| $ | 12,684 |
| $ | 11,329 |
|
|
|
|
|
| |||
Basic earnings per common share |
| $ | 0.17 |
| $ | 0.15 |
|
|
|
|
|
| |||
Diluted earnings per common share |
| $ | 0.17 |
| $ | 0.15 |
|
|
|
|
|
| |||
Basic weighted average number of common shares outstanding |
|
| 74,497 |
|
| 74,326 |
|
|
|
|
|
| |||
Diluted weighted average number of common shares outstanding |
|
| 74,518 |
|
| 74,333 |
|
HEALTHCARE SERVICES GROUP, INC. | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(Unaudited) | |||||
(in thousands) | |||||
| March 31, 2023 |
| December 31, 2022 | ||
Cash and cash equivalents | $ | 16,153 |
| $ | 26,279 |
Marketable securities, at fair value |
| 95,985 |
|
| 95,200 |
Accounts and notes receivable, net |
| 350,784 |
|
| 336,777 |
Other current assets |
| 47,165 |
|
| 50,376 |
Total current assets |
| 510,087 |
|
| 508,632 |
|
|
|
| ||
Property and equipment, net |
| 23,400 |
|
| 22,975 |
Notes receivable — long-term |
| 32,327 |
|
| 32,609 |
Goodwill |
| 75,529 |
|
| 75,529 |
Other intangible assets, net |
| 14,743 |
|
| 15,946 |
Deferred compensation funding |
| 34,312 |
|
| 33,493 |
Other assets |
| 28,735 |
|
| 29,150 |
Total assets | $ | 719,133 |
| $ | 718,334 |
|
|
|
| ||
Accrued insurance claims — current | $ | 23,974 |
| $ | 23,166 |
Other current liabilities |
| 138,190 |
|
| 155,453 |
Total current liabilities |
| 162,164 |
|
| 178,619 |
|
|
|
| ||
Accrued insurance claims — long-term |
| 67,100 |
|
| 65,541 |
Deferred compensation liability — long-term |
| 34,263 |
|
| 33,764 |
Lease liability — long-term |
| 8,586 |
|
| 8,097 |
Other long term liabilities |
| 6,448 |
|
| 6,141 |
Stockholders' equity |
| 440,572 |
|
| 426,172 |
Total liabilities and stockholders' equity | $ | 719,133 |
| $ | 718,334 |
HEALTHCARE SERVICES GROUP, INC. | |||||||
RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES | |||||||
(Unaudited) | |||||||
(in thousands) | |||||||
|
| For the three months ended | |||||
|
| ||||||
|
| 2023 |
| 2022 |
| ||
Reconciliation of Net Income to EBITDA and Adjusted EBITDA |
|
|
|
| |||
Net income |
| $ | 12,684 |
| $ | 11,329 |
|
Income tax provision |
|
| 4,872 |
|
| 4,452 |
|
Interest, net |
|
| 102 |
|
| (417 | ) |
Depreciation & amortization |
|
| 3,720 |
|
| 4,147 |
|
EBITDA |
| $ | 21,378 |
| $ | 19,511 |
|
Share-based compensation |
|
| 2,058 |
|
| 2,396 |
|
Gain/loss on deferred compensation, net |
|
| 44 |
|
| 289 |
|
Bad debt expense adjustments(1) |
|
| 4,035 |
|
| 1,108 |
|
Adjusted EBITDA |
| $ | 27,515 |
| $ | 23,304 |
|
(1) The bad debt expense adjustment reflects the difference between GAAP bad debt expense (CECL) and historical write-offs as a percentage of revenues, both of which are based on the same seven year look-back period. |
Last Trade: | US$11.68 |
Daily Change: | 0.16 1.39 |
Daily Volume: | 320,393 |
Market Cap: | US$857.080M |
October 23, 2024 July 24, 2024 April 24, 2024 February 14, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB